Pfizer Inc. (PFE)
PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer Use
Pfizer's Talzenna plus Xtandi combo wins FDA priority review for HRR gene-mutated metastatic castration-sensitive prostate cancer.
Pfizer's prostate cancer drug combination gets US FDA priority review
Pfizer said on Wednesday the U.S. Food and Drug Administration has granted priority review to its application seeking expanded approval for its prostate cancer treatment combination.
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season
Pfizer's non-oncology portfolio faced mixed Q2 trends. Eliquis and Vyndaqel sales may have risen while COVID products will have declined.
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Pfizer (PFE) closed at $24.75, marking a -1.2% move from the previous day.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?
PFE trades below key moving averages as investors weigh fading COVID sales against pipeline growth, acquisitions and a low valuation with a high dividend.
Stock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Pfizer (NYSE:PFE) both closed Q1 2026 with earnings beats, yet their post-report stories look nothing alike.
Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?
Pfizer (NYSE:PFE | PFE Price Prediction) trades at $24.25, against a Wall Street consensus price target of $28.79, which represents implied upside of almost 19%.
Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen
Pfizer (NYSE: PFE | PFE Price Prediction) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology.
Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results
PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.
Pfizer (PFE) Advances While Market Declines: Some Information for Investors
In the latest trading session, Pfizer (PFE) closed at $24.48, marking a +1.28% move from the previous day.
Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?
Abbott Laboratories (NYSE: ABT | ABT Price Prediction) and Pfizer (NYSE: PFE) both delivered Q1 2026 beats, yet the market treats them differently.
